Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CTT2274
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : National Cancer Institute
Deal Size : $2.4 million
Deal Type : Funding
Cancer Targeted Technology Receives $2.4M Grant for PSMA-Targeted Drug Conjugate
Details : The funding will be used to develop a new prodrug, CTT2274, that targets PSMA on prostate cancer and is designed to release a toxic drug, MMAE, within the cell that takes up the prodrug.
Brand Name : CTT2274
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 18, 2024
Lead Product(s) : CTT2274
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : National Cancer Institute
Deal Size : $2.4 million
Deal Type : Funding
Lead Product(s) : CTT1403
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : National Institutes of Health
Deal Size : $1.4 million
Deal Type : Funding
Details : The trial is designed to show safety and efficacy of CTT1403 and is halfway through the initial dose escalation phase. CTT1403 targets Prostate Specific Membrane Antigen (PSMA) which is over-expressed on prostate cancer.
Brand Name : CTT1403
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 07, 2020
Lead Product(s) : CTT1403
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : National Institutes of Health
Deal Size : $1.4 million
Deal Type : Funding
LOOKING FOR A SUPPLIER?
Reset All
